Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Potential Pharmacological Role of the TNF-Like Ligand 1A (TL1A) Inhibition in Modulating Systemic Sclerosis (SSc)-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept, In Vitro, Study

NCT07642297 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Campus Bio-Medico as lead sponsor.

NCT NCT07642297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07642297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Potential Pharmacological Role of the TNF-Like Ligand 1A (TL1A) Inhibition in Modulating Systemic Sclerosis (SSc)-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept, In Vitro, Study
Lead sponsor
Fondazione Policlinico Universitario Campus Bio-Medico
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse cutaneous systemic sclerosis, skin fibrosis, systemic sclerosis (ssc)